ERBB2 and breast carcinoma: They also reported that tribody [(HER2)2xCD16], which comprises two HER2-specific single chain fragment variables fused to a fragment antigen biding directed to the CD16 antigen expressed on γδ T cells and NK cells, enhanced γδ T cells and NK cells-mediated lysis of HER2-expressing tumor cells, such as pancreatic ductal adenocarcinoma, breast cancer, and autologous primary ovarian tumors [134].